Development and Validation of a Novel Model for Predicting Coronary Heart Disease in Snoring Hypertensive Patients with Hyperhomocysteinemia.


Journal

International heart journal
ISSN: 1349-3299
Titre abrégé: Int Heart J
Pays: Japan
ID NLM: 101244240

Informations de publication

Date de publication:
30 Nov 2023
Historique:
medline: 1 12 2023
pubmed: 16 11 2023
entrez: 15 11 2023
Statut: ppublish

Résumé

Hypertensive patients with snoring and elevated plasma homocysteine levels are common. When these factors are combined, the risk of coronary heart disease (CHD) is high. Herein, we developed and validated an easy-to-use nomogram to predict high-risk CHD in snoring hypertensive patients with elevated plasma homocysteine.Snoring patients (n = 1,962) with hyperhomocysteinemia and hypertension were divided into training (n = 1,373, 70%) and validation (n = 589, 30%) sets. We extracted CHD predictors using multivariate Cox regression analysis, then constructed a nomogram model. Internal validation using 1,000 bootstrap resampling was performed to assess the consistency and discrimination of the predictive model using the area under the receiver operating characteristic curve (AUC) and calibration plots.We constructed a nomogram model with the extracted predictors, including age, waist-height ratio, smoking, and low-density lipoprotein cholesterol levels. The AUCs of the training and validation cohorts at 80 months were 0.735 (95% CI: 0.678-0.792) and 0.646 (95% CI: 0.547-0.746), respectively. The consistency between the observed CHD survival and the probability of CHD survival in the training and validation sets was acceptable based on the calibration plots. A total of more than 151 points in the nomogram can be used in the identification of high-risk patients for CHD among snoring hypertensive patients with elevated plasma homocysteine.We developed a CHD risk prediction model for snoring hypertension patients with hyperhomocysteinemia. Our findings provide a useful clinical tool for the rapid identification of high-risk CHD at an early stage.

Identifiants

pubmed: 37967976
doi: 10.1536/ihj.23-384
doi:

Substances chimiques

Homocysteine 0LVT1QZ0BA

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

970-978

Auteurs

Jianwen Zhao (J)

Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region.

Menghui Wang (M)

Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region.

Nanfang Li (N)

Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region.

Qin Luo (Q)

Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region.

Ling Yao (L)

Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region.

Xintian Cai (X)

Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region.

Na Yue (N)

Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region.

Yingli Ren (Y)

Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region.

Guoliang Wang (G)

Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH